Aromatic nitrogen-containing 6-membered cyclic compounds
DCFirst Claim
1. An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I):
-
wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group;
R1 is a substituted or unsubstituted lower alkyl group, a group of the formula;
—
NH—
Q—
R3 (in which R3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or a group of the formula;
—
NH—
R4 (in which R4 is a substituted or unsubstituted cycloalkyl group);
R2 is a substituted or unsubstituted aryl group;
Z is a group of the formula;
═
CH—
, and Y is a group of the formula;
═
N—
, or a pharmaceutically acceptable salt thereof.
3 Assignments
Litigations
0 Petitions
Accused Products
Abstract
An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I):
wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R1 is a substituted or unsubstituted lower alkyl group, —NH—Q—R3 (R3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or —NH—R4 (R4 is a substituted or unsubstituted cycloalkyl group); R2 is a substituted or unsubstituted aryl group; one of Y and Z is ═CH—, and the other is ═N—, or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent selective PDE V inhibitory activities, and hence, being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.
29 Citations
22 Claims
-
1. An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I):
-
wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group;
R1 is a substituted or unsubstituted lower alkyl group, a group of the formula;
—
NH—
Q—
R3 (in which R3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or a group of the formula;
—
NH—
R4 (in which R4 is a substituted or unsubstituted cycloalkyl group);
R2 is a substituted or unsubstituted aryl group;
Z is a group of the formula;
═
CH—
, and Y is a group of the formula;
═
N—
, or a pharmaceutically acceptable salt thereof.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
or a nitrogen-containing heterobicyclic group of the following formula wherein the above-mentioned 5- or 6-membered nitrogen-containing heteromonocyclic group and a 5- or 6-membered cyclic group are fused;
and the nitrogen-containing heterocyclic group of the “
substituted or unsubstituted nitrogen-containing heterocyclic group”
for R3 is a nonaromatic nitrogen-containing heteromonocyclic group of the formula;
or an aromatic nitrogen-containing heterocyclic group of the formula;
or a pharmaceutically acceptable salt thereof.
-
-
4. The compound according to claim 1, wherein the nitrogen-containing heterocyclic group of the “
- substituted or unsubstituted nitrogen-containing heterocyclic group”
for Ring A is a 5- or 6-membered nitrogen-containing heteromonocyclic group or a 8- to 10-membered nitrogen-containing heterobicyclic group, and the substituent of the above “
substituted or unsubstituted nitrogen-containing heterocyclic group”
is selected from the group consisting of a lower alkyl group, a hydroxy-substituted lower alkyl group, a formyl group and an oxo group, R1 is a lower alkyl group which may optionally be substituted by a group selected from the group consisting of a lower alkoxy group and a morpholinyl group, a group of the formula;
—
NH—
Q—
R3, or a group of the formula;
—
NH—
R4, the “
substituted or unsubstituted nitrogen-containing heterocyclic group”
for R3 is a 5- or 6-membered nitrogen-containing heteromonocyclic group which may optionally be substituted by a lower alkyl group, R4 is a cycloalkyl group being substituted by a group selected from the group consisting of hydroxy group and a lower alkoxy group, R2 is a phenyl group being substituted by a group selected from the group consisting of a lower alkoxy group, a halogen atom and a cyano group.
- substituted or unsubstituted nitrogen-containing heterocyclic group”
-
5. The compound according to claim 4, wherein the nitrogen-containing heterocyclic group of the “
- substituted or unsubstituted nitrogen-containing heterocyclic group”
for Ring A is a 5- or 6-membered non-aromatic nitrogen-containing heteromonocyclic group of the formula;
or a nitrogen-containing heterobicyclic group of the following formula wherein the above-mentioned 5- or 6-membered non-aromatic nitrogen-containing heteromonocyclic group and a 5- or 6-membered aromatic nitrogen-containing heteromonocyclic group are fused;
the nitrogen-containing heterocyclic group of the “
substituted or unsubstituted nitrogen-containing heterocyclic group”
for R3 is a non-aromatic nitrogen-containing heteromonocyclic group of the formula;
or an aromatic nitrogen-containing heteromonocyclic group of the formula;
- substituted or unsubstituted nitrogen-containing heterocyclic group”
-
6. The compound according to claim 1, wherein Ring A is a group of the formula:
-
R1 is a lower alkyl group, a lower alkoxy-substituted lower alkyl group, a morpholinyl-substituted lower alkyl group, a group of the formula;
—
NH—
Q—
R3, or a group of the formula;
—
NH—
R4, R3 is a group of the formula;
R4 is a group of the formula;
and R2 is a group of the formula;
-
-
7. The compound according to claim 1, wherein the nitrogen-containing heterocyclic group of the “
- substituted or unsubstituted nitrogen-containing heterocyclic group”
for Ring A is a 5- or 6-membered nitrogen-containing heteromonocyclic group or a 8- to 10-membered nitrogen-containing heterobicyclic group, and the substituent of the above “
substituted or unsubstituted nitrogen-containing heterocyclic group”
is a group selected from the group consisting of a lower alkyl group, a hydroxy-substituted lower alkyl group, a formyl group and an oxo group, R1 is a lower alkoxy-substituted lower alkyl group, a group of the formula;
—
NH—
Q—
R3, or a group of the formula;
—
NH—
R4, the “
substituted or unsubstituted nitrogen-containing heterocyclic group”
for R3 is a 5- or 6-membered nitrogen-containing heteromonocyclic group which may optionally be substituted by a lower alkyl group, R4 is a hydroxy-substituted cycloalkyl group, and R2 is a phenyl group being substituted by a group selected from the group consisting of a lower alkoxy group and a halogen atom.
- substituted or unsubstituted nitrogen-containing heterocyclic group”
-
8. The compound according to claim 7, wherein the nitrogen-containing heterocyclic group of the “
- substituted or unsubstituted nitrogen-containing heterocyclic group”
for Ring A is a 5- or 6-membered non-aromatic nitrogen-containing heteromonocyclic group of the formula;
a group of the formula;
the nitrogen-containing heterocyclic group of the “
substituted or unsubstituted nitrogen-containing heterocyclic group”
for R3 is a non-aromatic nitrogen-containing heteromonocyclic group of the formula;
or an aromatic nitrogen-containing heteromonocyclic group of the formula;
- substituted or unsubstituted nitrogen-containing heterocyclic group”
-
9. The compound according to claim 1, wherein Ring A is a group of the formula:
-
R1 is a lower alkoxy-substituted lower alkyl group, a group of the formula;
—
NH—
Q—
R3, or a group of the formula;
—
NH—
R4, R3 is a group of the formula;
R4 is a group of the formula;
and R2 is a group of the formula;
-
-
10. The compound according to claim 1, wherein the nitrogen-containing heterocyclic group of the “
- substituted or unsubstituted nitrogen-containing heterocyclic group”
for Ring A is a 5- or 6-membered nitrogen-containing heteromonocyclic group or a 8- to 10-membered nitrogen-containing heterobicyclic group, and the substituent of the above “
substituted or unsubstituted nitrogen-containing heterocyclic group”
is a hydroxy-substituted lower alkyl group, R1 is a group of the formula;
—
NH—
Q—
R3, the “
substituted or unsubstituted nitrogen-containing heterocyclic group”
for R3 is a 5- or 6-membered nitrogen-containing heteromonocyclic group which may optionally be substituted by a lower alkyl group, and R2 is a phenyl group being substituted by a group selected from the group consisting of a lower alkoxy group and a halogen atom.
- substituted or unsubstituted nitrogen-containing heterocyclic group”
-
11. The compound according to claim 10, wherein the nitrogen-containing heterocyclic group of the “
- substituted or unsubstituted nitrogen-containing heterocyclic group”
for Ring A is a 5- or 6-membered non-aromatic nitrogen-containing heteromonocyclic group of the formula;
or a group of the formula;
the nitrogen-containing heterocyclic group of the “
substituted or unsubstituted nitrogen-containing heterocyclic group”
for R3 is a non-aromatic nitrogen-containing heteromonocyclic group of the formula;
or an aromatic nitrogen-containing heteromonocyclic group of the formula;
- substituted or unsubstituted nitrogen-containing heterocyclic group”
-
12. The compound according to claim 1, wherein Ring A is a group of the formula:
-
R1 is a group of the formula;
—
NH—
Q—
R3, R3 is a group of the formula;
and R2 is a group of the formula;
-
-
13. The compound according to claim 1, wherein said compound is selected from the group consisting of:
-
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidime;
2-(6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-6-yl)-4-(3-cyano-4-methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine;
2-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-7-yl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(trans-4-methoxycyclohexyl)carbamoyl]pyrimidine;
2-(6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-6-yl)-4-(3-cyano-4-methoxybenzylamino)-5-[N-(trans-4-hydroxycyclohexyl)carbamoyl]pyrimidine;
2-(6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-6-yl)-4-(3-cyano-4-methoxybenzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)4-(3-chloro-4-methoxy-benzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine;
2-[(2S)-2-hydroxymethyl-1-pyrrolidinyl]-4-(3-chloro-4-methoxy-benzylamino)-5-[N-[[(2R)-4-methyl-2-morpholinyl]methyl]carbamoyl]pyrimidine;
2-[(2S)-2-hydroxymethyl-1-pyrrolidinyl]-4-(3-chloro-4-methoxy-benzylamino)-5-[N-[[(2S)-4-methyl-2-morpholinyl]methyl]carbamoyl]pyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxy-benzylamino)-5-[N-(4-pyrimidinylmethyl)carbamoyl]pyrimidine;
2-(4-methyl-3-oxo-I-piperazinyl)-4-(3-chloro-4-methoxybenzyl-amino)-5-[N-(trans-4-hydroxycyclohexyl)carbamoyl]pyrimidine;
2-(4-formyl-1-piperazinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(trans-4-hydroxycyclohexyl)carbamoyl]pyrimidine;
2-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-7-yl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(trans-4-hydroxycyclohexyl)carbamoyl]pyrimidine;
2-[cis-2,5-bis(hydroxymethyl)-1-pyrrolidinyl]-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine, 2-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-7-yl)-4-(3-chloro-4-methoxy-benzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine;
2-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-7-yl)-4-(3-chloro-4-methoxy-benzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine;
2-(5,6,7,8-tetrahydro-1,7-naphthyridin-7-yl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-acethylpyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(4-pyridazinylmethyl)carbamoyl]pyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(5-pyridazinylmethyl)carbamoyl]pyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine;
2-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-7-yl)-4-(3-chloro-4-methoxy-benzylamino)-5-[N-[(4-methyl-2-morpholinyl)methyl]carbamoyl]pyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[(2-methoxyethyl)carbonyl]pyrimidine; and
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(1,3,5-trimethyl-4-pyrazolyl)carbamoyl]pyrimidine, or a pharmaceutically acceptable salt thereof.
-
-
14. The compound according to claim 13, wherein said compound is selected from the group consisting of:
-
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)5-[N-(4-pyrimidinylmethyl)carbamoyl]pyrimidine;
2-(4-methyl-3-oxo-1-piperazinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(trans-4-hydroxycyclohexyl)carbamoyl]pyrimidine;
2-(4-formyl-1-piperazinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(trans-4-hydroxycyclohexyl)carbamoyl]pyrimidine;
2-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-7-yl)-4-(3-chloro-4-methoxy-benzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine;
2-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-7-yl)-4-(3-chloro-4-methoxy-benzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine;
2-(5,6,7,8-tetrahydro-1,7-naphthyridin-7-yl)-4-(3-chloro-4-methoxybenzylamino)5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-pyrimidinylmethyl)carbamoyl]pyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[(2-methoxyethyl)carbonyl]pyrimidine; and
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxy-benzylamino)-5-[N-(1,3,5-trimethyl-4-pyrazolyl)carbamoyl]pyrimidine, or a pharmaceutically acceptable salt thereof.
-
-
15. The compound according to claim 13, wherein said compound is selected from the group consisting of:
-
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine;
2-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-7-yl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine;
2-(5,6,7,8-tetrahydro-1,7-naphthyridin-7-yl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine;
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5[N-(5-pyrimidinylmethyl)carbamoyl]pyrimidine; and
(S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(1,3,5-trimethyl-4-pyrazolyl)carbamoyl]pyrimidine, or a pharmaceutically acceptable salt thereof.
-
-
16. The compound of claim 13, wherein said compound is (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine, or a pharmaceutically acceptable salt thereof.
-
17. The compound of claim 13, wherein said compound is 2-(5,6,7,8-tetrahydro-1,7-naphthyridin-7-yl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-morpholinoethyl)carbamoyl]pyrimidine, or a pharmaceutically acceptable salt thereof.
-
18. The compound of claim 13, wherein said compound is (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(1,3,5-trimethyl-4-pyrazolyl)carbamoyl]pyrimidine, or a pharmaceutically acceptable salt thereof.
-
19. A pharmaceutical composition, which contains as an active ingredient the compound as set forth in any one of claims 1-12 and 13-18, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.
-
20. A method for treatment of penile erectile dysfunction, which comprises administering to a patient in need thereof an effective amount of the compound as set forth in any one of claims 1-12 and 13-18, or a pharmaceutically acceptable salt thereof.
-
21. A method for treatment of pulmonary hypertension, which comprises administering to a patient in need thereof an effective amount of the compound as set forth in any one of claims 1-12 and 24-18, or a pharmaceutically acceptable salt thereof.
-
22. A method for treatment of diabetic gastroparesis, which comprises administering to a patient in need thereof an effective amount of the compound as set forth in any one of claims 1-12 and 13-18, or a pharmaceutically acceptable salt thereof.
Specification